Axsome Therapeutics (AXSM) Projected to Post Quarterly Earnings on Monday

Key Points

• Axsome Therapeutics is set to announce its Q2 2025 earnings on August 4th, with expectations of a loss of ($1.04) per share and revenue of $140.02 million.
• The company's stock is currently down 3.9% and has a market capitalization of approximately $4.96 billion.
• Recent insider trading activity includes General Counsel Hunter R. Murdock selling 7,500 shares, raising concerns as corporate insiders have sold a total of 93,437 shares worth about $9.83 million over the last three months.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) is projected to announce its Q2 2025 earnings results before the market opens on Monday, August 4th. Analysts expect the company to announce earnings of ($1.04) per share and revenue of $140.02 million for the quarter.

Axsome Therapeutics Stock Performance

Shares of Axsome Therapeutics stock traded up $0.66 during trading on Thursday, reaching $101.92. The company's stock had a trading volume of 225,084 shares, compared to its average volume of 788,640. Axsome Therapeutics has a one year low of $72.21 and a one year high of $139.13. The firm has a market cap of $5.02 billion, a price-to-earnings ratio of -17.66 and a beta of 0.46. The business's fifty day moving average price is $105.94 and its 200-day moving average price is $110.20. The company has a debt-to-equity ratio of 3.48, a quick ratio of 1.96 and a current ratio of 2.03.

Analyst Upgrades and Downgrades

AXSM has been the topic of a number of recent research reports. Morgan Stanley started coverage on Axsome Therapeutics in a research report on Thursday, July 3rd. They set an "overweight" rating and a $190.00 target price on the stock. Needham & Company LLC decreased their price objective on Axsome Therapeutics from $153.00 to $150.00 and set a "buy" rating on the stock in a report on Monday, June 9th. Cantor Fitzgerald raised Axsome Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. Royal Bank Of Canada decreased their price objective on Axsome Therapeutics from $193.00 to $186.00 and set an "outperform" rating on the stock in a report on Thursday, June 12th. Finally, Wells Fargo & Company reiterated an "overweight" rating and issued a $165.00 target price (up previously from $160.00) on shares of Axsome Therapeutics in a research note on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $172.33.

Insider Buying and Selling

In related news, General Counsel Hunter R. Murdock sold 7,500 shares of the company's stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $100.26, for a total value of $751,950.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Mark L. Jacobson sold 25,000 shares of the stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $110.44, for a total transaction of $2,761,000.00. Following the transaction, the chief operating officer owned 5,783 shares of the company's stock, valued at approximately $638,674.52. This represents a 81.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 93,437 shares of company stock valued at $9,834,215. Company insiders own 22.30% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AXSM. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Axsome Therapeutics by 29.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company's stock worth $8,735,000 after purchasing an additional 17,250 shares during the period. Caxton Associates LLP acquired a new stake in shares of Axsome Therapeutics during the 1st quarter worth approximately $307,000. Goldman Sachs Group Inc. boosted its position in shares of Axsome Therapeutics by 38.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company's stock worth $35,189,000 after acquiring an additional 84,151 shares in the last quarter. Jones Financial Companies Lllp boosted its position in shares of Axsome Therapeutics by 2,407.9% during the 1st quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company's stock worth $889,000 after acquiring an additional 7,320 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Axsome Therapeutics by 4.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company's stock worth $2,557,000 after acquiring an additional 1,002 shares in the last quarter. 81.49% of the stock is owned by institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.